Colin Walsh, Ph.D. is a partner at Qiming Venture Partners USA. He currently serves on the board of Korro Bio and Elevation Oncology and is a board observer of Amphivena Therapeutics and Icosavax.
Before joining Qiming in 2019, Colin was a vice president on the life science investment team at ND Capital where he sourced, structured and managed investments in biotech, biopharma and platform companies. Prior to ND, he held a number of roles as an early employee at Precision NanoSystems, a 5AM Ventures backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations.
Colin earned a Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering where he worked on novel delivery systems for RNA therapeutics as an NSF Graduate Research Fellow. He holds a Management of Technology certificate from the UC Berkeley Haas School of Business and a dual B.S. with Honors in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst.
Colin currently serves on the business advisory board for the Harvard Medical School Initiative for RNA Medicine. He is also an advisor to the Stanford SPARK program and the UCSF Catalyst program where he provides mentorship and support to student- and faculty-led translational research projects.